These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 26096855)

  • 21. Potency evaluation of tissue engineered and regenerative medicine products.
    Guthrie K; Bruce A; Sangha N; Rivera E; Basu J
    Trends Biotechnol; 2013 Sep; 31(9):505-14. PubMed ID: 23932143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Regulatory science research to facilitate the development of cell/tissue-processed products].
    Sato Y; Tsutsumi H; Sawada R; Suzuki T; Yasuda S
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2013; (131):16-9. PubMed ID: 24340665
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Establishing a Quality Control System for Stem Cell-Based Medicinal Products in China.
    Yuan BZ
    Tissue Eng Part A; 2015 Dec; 21(23-24):2783-90. PubMed ID: 25471126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulatory enablers and regulatory challenges for the development of tissue-engineered products in the EU.
    Brévignon-Dodin L
    Biomed Mater Eng; 2010; 20(3):121-6. PubMed ID: 20930319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulatory issues in cell-based therapy for clinical purposes.
    Casaroli-Marano RP; Tabera J; Vilarrodona A; Trias E
    Dev Ophthalmol; 2014; 53():189-200. PubMed ID: 24732772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [European Marketing Authorisation: a long process. Experiences of small biotech companies with the ATMP regulation].
    Buljovčić Z
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):831-8. PubMed ID: 21698536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The expanding role of the clinical haematologist in the new world of advanced therapy medicinal products.
    Lowdell MW; Thomas A
    Br J Haematol; 2017 Jan; 176(1):9-15. PubMed ID: 27748517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a cell-based medicinal product: regulatory structures in the European Union.
    Gálvez P; Clares B; Hmadcha A; Ruiz A; Soria B
    Br Med Bull; 2013; 105():85-105. PubMed ID: 23184855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Current concept for the microbiological safety of cell-based medicinal products].
    Schurig U; Karo JO; Sicker U; Spindler-Raffel E; Häckel L; Spreitzer I; Bekeredjian-Ding I
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1225-32. PubMed ID: 26369764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulation of tissue-engineered products in the European Union: where are we heading?
    Brévignon-Dodin L; Livesey F
    Regen Med; 2006 Sep; 1(5):709-14. PubMed ID: 17465739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Report from the Committee for Advanced Therapies (CAT). Pitfalls on the way from concept to medical treatment with advanced therapy medicinal products].
    Reiss M; Büttel IC; Schneider CK
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):822-30. PubMed ID: 21698535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Current State of Advanced Therapy Medicinal Products in the Czech Republic.
    Kočí Z; Boráň T; Krůpa P; Kubinová Š
    Hum Gene Ther Clin Dev; 2018 Sep; 29(3):132-147. PubMed ID: 29869533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Process control: application to the cell processing laboratory.
    Keever-Taylor CA
    Cytotherapy; 2000; 2(1):63-73. PubMed ID: 12042057
    [No Abstract]   [Full Text] [Related]  

  • 34. The regulation of allogeneic human cells and tissue products as biomaterials.
    Yano K; Tsuyuki K; Watanabe N; Kasanuki H; Yamato M
    Biomaterials; 2013 Apr; 34(13):3165-73. PubMed ID: 23410682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies.
    Abbasalizadeh S; Baharvand H
    Biotechnol Adv; 2013 Dec; 31(8):1600-23. PubMed ID: 23962714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Classification of cell-based medicinal products and legal implications: An overview and an update].
    Scherer J; Flory E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1201-6. PubMed ID: 26369760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of cell-based therapeutic products intended for human applications in the EU.
    Närhi MO; Nordström K
    Regen Med; 2014 May; 9(3):327-51. PubMed ID: 24935044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A critical assessment of the directive on tissue engineering of the European union.
    Trommelmans L; Selling J; Dierickx K
    Tissue Eng; 2007 Apr; 13(4):667-72. PubMed ID: 17253926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Strategic considerations on the design and choice of animal models for non-clinical investigations of cell-based medicinal products].
    Lehmann J; Schulz RM; Sanzenbacher R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1215-24. PubMed ID: 26431722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Problems in microbial safety of advanced therapy medicinal products. Squaring the circle].
    Montag-Lessing T; Störmer M; Schurig U; Brachert J; Bubenzer M; Sicker U; Beshir R; Spreitzer I; Löschner B; Bache C; Becker B; Schneider CK
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):45-51. PubMed ID: 20012926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.